We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+55.06%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.8B
AUM Growth
+$694M
Cap. Flow
+$99M
Cap. Flow %
3.54%
Top 10 Hldgs %
54.31%
Holding
75
New
7
Increased
22
Reduced
25
Closed
5

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$63.5M
2
IMNM icon
Immunome
IMNM
+$32.3M
3
BHVN icon
Biohaven
BHVN
+$28.8M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$27.9M
5
ABT icon
Abbott
ABT
+$26.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$30M
2
HUM icon
Humana
HUM
+$29.1M
3
ELV icon
Elevance Health
ELV
+$28.8M
4
FOLD
Amicus Therapeutics
FOLD
+$24M
5
DXCM icon
DexCom
DXCM
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.15%
2 Industrials 3.43%
3 Miscellaneous 2.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
26
IDEAYA Biosciences
IDYA
$3.87B
$33.3M 1.19%
+935,863
New +$27.9M
REPL icon
27
Replimune Group
REPL
$1.46B
$32.6M 1.17%
3,865,258
-298,664
-7% -$3.46M
CABA icon
28
Cabaletta Bio
CABA
$529M
$31.2M 1.12%
1,374,189
-400,063
-23% -$6.73M
ABT icon
29
Abbott
ABT
$195B
$29.2M 1.05%
+265,500
New +$26.5M
EVH icon
30
Evolent Health
EVH
$520M
$27.6M 0.99%
835,537
+370,255
+80% +$10.5M
AKRO
31
DELISTED
Akero Therapeutics
AKRO
$25.9M 0.93%
1,109,476
-660,208
-37% -$13M
ADCT icon
32
ADC Therapeutics
ADCT
$146M
$25.4M 0.91%
15,328,317
+1,150,272
+8% +$1.06M
ANNX icon
33
Annexon
ANNX
$942M
$25M 0.89%
5,503,190
+2,000,000
+57% +$4.95M
IGMS
34
DELISTED
IGM Biosciences
IGMS
$24.7M 0.88%
2,971,542
– –
VERV
35
DELISTED
Verve Therapeutics
VERV
$24M 0.86%
1,718,669
+908,892
+112% +$11.3M
PEN icon
36
Penumbra
PEN
$12.7B
$24M 0.86%
95,242
-59,834
-39% -$13.2M
ETNB
37
DELISTED
89bio
ETNB
$22M 0.79%
1,969,402
+1,207,447
+158% +$11.1M
CRL icon
38
Charles River Laboratories
CRL
$13.9B
$20.5M 0.73%
86,782
+20,400
+31% +$4.01M
TRDA icon
39
Entrada Therapeutics
TRDA
$273M
$19.4M 0.69%
1,283,735
-265
-0% -$3.93K
NGNE icon
40
Neurogene
NGNE
$732M
$18.4M 0.66%
946,897
+801,286
+550% +$11.5M
ISRG icon
41
Intuitive Surgical
ISRG
$132B
$18.3M 0.65%
+54,258
New +$16.2M
HCA icon
42
HCA Healthcare
HCA
$90.5B
$17.9M 0.64%
66,100
+41,433
+168% +$10.2M
COGT icon
43
Cogent Biosciences
COGT
$6.02B
$17.1M 0.61%
2,914,022
+860,689
+42% +$6.6M
SYK icon
44
Stryker
SYK
$127B
$15.9M 0.57%
53,141
-41,597
-44% -$11.7M
RPTX
45
DELISTED
Repare Therapeutics
RPTX
$15.7M 0.56%
2,148,748
-255,947
-11% -$1.43M
STOK icon
46
Stoke Therapeutics
STOK
$2.04B
$13.8M 0.49%
2,625,506
-1,247,190
-32% -$5.33M
ALGN icon
47
Align Technology
ALGN
$11.2B
$13.7M 0.49%
+50,082
New +$11.9M
GRTS
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$12M 0.43%
5,872,605
-2,636,521
-31% -$4.81M
PRME icon
49
Prime Medicine
PRME
$655M
$11.7M 0.42%
1,324,350
– –
ELV icon
50
Elevance Health
ELV
$85.5B
$10.9M 0.39%
23,079
-62,299
-73% -$28.8M
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2023 Portfolio in Review

As of Q4 2023, Redmile Group held 75 positions worth $2.8B, up 33% from $2.1B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Redmile Group deployed $99M of net new capital in Q4 2023, opening 7 new positions and adding to 22 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 142,500 shares worth $67.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Krystal Biotech, an estimated $30M trimmed.

  • Redmile Group's largest Q4 2023 buy was State Street SPDR S&P 500 ETF Trust: 142,500 shares worth $67.7M.
  • Redmile Group added most to Biohaven in Q4 2023, an estimated $28.8M increase.
  • Redmile Group's biggest Q4 2023 reduction was Krystal Biotech, cutting an estimated $30M.
  • Redmile Group fully exited Humana in Q4 2023, selling an estimated $29.1M.
  • Redmile Group's ten largest holdings make up 54% of its $2.8B portfolio in Q4 2023.
  • Redmile Group opened 7 new positions and closed 5 in Q4 2023.
  • Redmile Group's portfolio value rose 33% quarter-over-quarter to $2.8B.

Based on Redmile Group's 13F filing for Q4 2023, filed 14 Feb 2024.